Elisabetta Gavini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2633823/publications.pdf

Version: 2024-02-01

83 papers 3,315 citations

32 h-index 54 g-index

85 all docs 85 does citations

85 times ranked 4522 citing authors

#	Article	IF	CITATIONS
1	Surfactant-Free Chitosan/Cellulose Acetate Phthalate Nanoparticles: An Attempt to Solve the Needs of Captopril Administration in Paediatrics. Pharmaceuticals, 2022, 15, 662.	1.7	6
2	Novel Utilization of Therapeutic Coatings Based on Infiltrated Encapsulated Rose Bengal Microspheres in Porous Titanium for Implant Applications. Pharmaceutics, 2022, 14, 1244.	2.0	5
3	Antibacterial activity of Zn-loaded Cuban zeolite against Helicobacter pylori in comparison to its Na-loaded and unmodified counterparts. Environmental Geochemistry and Health, 2021, 43, 2037-2048.	1.8	5
4	Polymeric nanomicelles based on inulin D \hat{l} ±-tocopherol succinate for the treatment of diabetic retinopathy. Journal of Drug Delivery Science and Technology, 2021, 61, 102286.	1.4	8
5	Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport. Pharmaceutics, 2021, 13, 267.	2.0	23
6	Nanotechnology-based rose Bengal: A broad-spectrum biomedical tool. Dyes and Pigments, 2021, 188, 109236.	2.0	45
7	Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?. Pharmaceutics, 2021, 13, 670.	2.0	21
8	Crocetin as New Cross-Linker for Bioactive Sericin Nanoparticles. Pharmaceutics, 2021, 13, 680.	2.0	8
9	Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?. Pharmaceutics, 2021, 13, 1180.	2.0	13
10	Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible "EPR Effect Enhancer―to Improve Cancer Nanomedicine Efficacy. Cancers, 2021, 13, 4437.	1.7	17
11	Improving Dermal Delivery of Rose Bengal by Deformable Lipid Nanovesicles for Topical Treatment of Melanoma. Molecular Pharmaceutics, 2021, 18, 4046-4057.	2.3	25
12	Investigation of Cytotoxicity and Cell Uptake of Cationic Beta-Cyclodextrins as Valid Tools in Nasal Delivery. Pharmaceutics, 2020, 12, 658.	2.0	20
13	Solid Lipid Nanoparticles as Formulative Strategy to Increase Oral Permeation of a Molecule Active in Multidrug-Resistant Tuberculosis Management. Pharmaceutics, 2020, 12, 1132.	2.0	19
14	Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting. Nanomaterials, 2020, 10, 870.	1.9	33
15	<p>Clinical Assessment of New Topical Cream Containing Two Essential Oils Combined with Tretinoin in the Treatment of Acne</p> . Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 233-239.	0.8	34
16	Nose-to-Brain Delivery. Pharmaceutics, 2020, 12, 138.	2.0	36
17	Indocyanine Green Loaded Polymeric Nanoparticles: Physicochemical Characterization and Interaction Studies with Caco-2 Cell Line by Light and Transmission Electron Microscopy. Nanomaterials, 2020, 10, 133.	1.9	10
18	Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases. Pharmaceutics, 2020, 12, 1246.	2.0	15

#	Article	IF	CITATIONS
19	Antibacterial activity of Na-clinoptilolite against Helicobacter pylori: in-vitro tests, synergistic effect with amoxicillin and stability of the antibiotic formulated with the zeolite. Microporous and Mesoporous Materials, 2019, 288, 109592.	2.2	8
20	Sustained Release from Injectable Composite Gels Loaded with Silver Nanowires Designed to Combat Bacterial Resistance in Bone Regeneration Applications. Pharmaceutics, 2019, 11, 116.	2.0	25
21	Poly (ethyl 2-cyanoacrylate) nanoparticles (PECA-NPs) as possible agents in tumor treatment. Colloids and Surfaces B: Biointerfaces, 2019, 177, 520-528.	2.5	10
22	Nanoemulsions for "Nose-to-Brain―Drug Delivery. Pharmaceutics, 2019, 11, 84.	2.0	158
23	Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinson's Disease. Current Stem Cell Research and Therapy, 2019, 14, 549-569.	0.6	13
24	Intranasal Delivery of Genistein-Loaded Nanoparticles as a Potential Preventive System against Neurodegenerative Disorders. Pharmaceutics, 2019, 11, 8.	2.0	66
25	Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases?. Phytomedicine, 2019, 52, 23-31.	2.3	38
26	Lymph node metastases: importance of detection and treatment strategies. Expert Opinion on Drug Delivery, 2018, 15, 459-467.	2.4	26
27	Aqueous injection of quercetin: An approach for confirmation of its direct in vivo cardiovascular effects. International Journal of Pharmaceutics, 2018, 541, 224-233.	2.6	23
28	Prolonged skin retention of clobetasol propionate by bio-based microemulsions: a potential tool for scalp psoriasis treatment. Drug Development and Industrial Pharmacy, 2018, 44, 398-406.	0.9	15
29	Hydroxypropyl-Î ² -Cyclodextrin Formulated in Nasal Chitosan Microspheres as Candidate Therapeutic Agent in Alzheimer's Disease. Current Drug Delivery, 2018, 15, 746-748.	0.8	9
30	The Role of Combined Penetration Enhancers in Nasal Microspheres on In Vivo Drug Bioavailability. Pharmaceutics, 2018, 10, 206.	2.0	31
31	Nanoparticles in detection and treatment of lymph node metastases: an update from the point of view of administration routes. Expert Opinion on Drug Delivery, 2018, 15, 1117-1126.	2.4	6
32	Biodegradable Microspheres as Intravitreal Delivery Systems for Prolonged Drug Release. What is their Eminence in the Nanoparticle Era?. Current Drug Delivery, 2018, 15, 930-940.	0.8	15
33	Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. Colloids and Surfaces B: Biointerfaces, 2017, 152, 296-301.	2.5	163
34	In situ forming biodegradable poly($\hat{l}\mu$ -caprolactone) microsphere systems: a challenge for transarterial embolization therapy. In vitro and preliminary ex vivo studies. Expert Opinion on Drug Delivery, 2017, 14, 453-465.	2.4	7
35	Engineered polymeric microspheres obtained by multi-step method as potential systems for transarterial embolization and intraoperative imaging of HCC: Preliminary evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 160-167.	2.0	20
36	Natural collagenic skeleton of marine sponges in pharmaceutics: Innovative biomaterial for topical drug delivery. Materials Science and Engineering C, 2017, 70, 710-720.	3.8	53

#	Article	IF	Citations
37	The effect of formulative parameters on the size and physical stability of SLN based on "green― components. Pharmaceutical Development and Technology, 2016, 21, 98-107.	1.1	15
38	Bio-based topical system for enhanced salicylic acid delivery: preparation and performance of gels. Journal of Pharmacy and Pharmacology, 2016, 68, 999-1009.	1.2	19
39	Neuroprotective Effects of Engineered Polymeric Nasal Microspheres Containing Hydroxypropyl-β-cyclodextrin on β-Amyloid (1-42)–Induced Toxicity. Journal of Pharmaceutical Sciences, 2016, 105, 2372-2380.	1.6	29
40	Indocyanine green delivery systems for tumour detection and treatments. Biotechnology Advances, 2016, 34, 768-789.	6.0	143
41	Synthesis of 2â€(Quinoxalinâ€2â€ylaminoâ€benzotriazolyl) Pentanedioic Derivatives as Potential Antiâ€Folate Agents. Journal of Heterocyclic Chemistry, 2016, 53, 1721-1737.	1.4	3
42	Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases. Carbohydrate Polymers, 2016, 136, 1338-1347.	5.1	93
43	Natural zeolites for pharmaceutical formulations: Preparation and evaluation of a clinoptilolite-based material. Microporous and Mesoporous Materials, 2016, 223, 58-67.	2.2	48
44	Engineered microparticles based on drug–polymer coprecipitates for ocular-controlled delivery of Ciprofloxacin: influence of technological parameters. Drug Development and Industrial Pharmacy, 2016, 42, 554-562.	0.9	12
45	Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. Journal of Drug Delivery Science and Technology, 2016, 32, 77-87.	1.4	66
46	Solid microparticles based on chitosan or methyl- \hat{l}^2 -cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. Journal of Controlled Release, 2015, 201, 68-77.	4.8	116
47	Development of thermosensitive chitosan/glicerophospate injectablein situgelling solutions for potential application in intraoperative fluorescence imaging and local therapy of hepatocellular carcinoma: a preliminary study. Expert Opinion on Drug Delivery, 2015, 12, 1583-1596.	2.4	30
48	From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery. European Journal of Pharmaceutical Sciences, 2015, 74, 63-76.	1.9	18
49	Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Research, 2015, 123, 146-157.	1.9	56
50	Propolis as lipid bioactive nano-carrier for topical nasal drug delivery. Colloids and Surfaces B: Biointerfaces, 2015, 136, 908-917.	2.5	29
51	Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. European Journal of Medicinal Chemistry, 2015, 105, 63-79.	2.6	38
52	Improvement of thymol properties by complexation with cyclodextrins: In vitro and in vivo studies. Carbohydrate Polymers, 2014, 102, 393-399.	5.1	71
53	Encapsulation and modified-release of thymol from oral microparticles as adjuvant or substitute to current medications. Phytomedicine, 2014, 21, 1627-1632.	2.3	23
54	Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 174-183.	2.0	53

#	Article	IF	Citations
55	Evaluation of the effect of hydroxypropyl- \hat{l}^2 -cyclodextrin on topical administration of milk thistle extract. Carbohydrate Polymers, 2013, 92, 40-47.	5.1	23
56	Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opinion on Drug Delivery, 2013, 10, 679-690.	2.4	27
57	Transarterial chemoembolization of hepatocellular carcinoma – agents and drugs: an overview. Part 2. Expert Opinion on Drug Delivery, 2013, 10, 799-810.	2.4	41
58	Studies of Technological Parameters Influencing the Protein-Polymeric Nanoparticles Adsorption Process for Transmucosal Administration. Current Nanoscience, 2012, 8, 819-829.	0.7	2
59	Solid lipid nanoparticles with and without hydroxypropyl- \hat{l}^2 -cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery. Nanotechnology, 2012, 23, 095101.	1.3	23
60	Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC–ESI-MS/MS analysis: Application to in vivo preclinical pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 901, 72-78.	1.2	16
61	Mucoadhesive Drug Delivery Systems for Nose-to-Brain Targeting of Dopamine. Journal of Nanoneuroscience, 2012, 2, 47-55.	0.5	8
62	Development of solid nanoparticles based on hydroxypropyl- $\langle i \rangle \hat{l}^2 \langle i \rangle$ -cyclodextrin aimed for the colonic transmucosal delivery of diclofenac sodium. Journal of Pharmacy and Pharmacology, 2011, 63, 472-482.	1.2	27
63	Surface Thermodynamics of Mucoadhesive Dry Powder Formulation of Zolmitriptan. AAPS PharmSciTech, 2011, 12, 1186-1192.	1.5	22
64	Influence of Chitosan Glutamate on the in vivo Intranasal Absorption of Rokitamycin from Microspheres. Journal of Pharmaceutical Sciences, 2011, 100, 1488-1502.	1.6	51
65	Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studiesâ€. Journal of Pharmacy and Pharmacology, 2010, 57, 287-294.	1.2	104
66	Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. Journal of Pharmacy and Pharmacology, 2010, 59, 1057-1064.	1.2	98
67	Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. Journal of Pharmacy and Pharmacology, 2010, 61, 559-567.	1.2	37
68	New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration. Journal of Pharmaceutical Sciences, 2009, 98, 4852-4865.	1.6	43
69	Frontal polymerization as a new method for developing drug controlled release systems (DCRS) based on polyacrylamide. European Polymer Journal, 2009, 45, 690-699.	2.6	61
70	Mucoadhesive microspheres for nasal administration of cyclodextrins. Journal of Drug Targeting, 2009, 17, 168-179.	2.1	37
71	Galactosyl Prodrug of Ketorolac: Synthesis, Stability, and Pharmacological and Pharmacokinetic Evaluations. Journal of Medicinal Chemistry, 2009, 52, 3794-3800.	2.9	22
72	Brain uptake of an anti-ischemic agent by nasal administration of microparticles. Journal of Pharmaceutical Sciences, 2008, 97, 4889-4903.	1.6	62

#	Article	IF	Citations
73	Ketoprofen Spray-dried Microspheres Based on Eudragit® RS and RL: Study of the Manufacturing Parameters. Drug Development and Industrial Pharmacy, 2008, 34, 1178-1187.	0.9	27
74	Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 245-252.	2.0	72
75	A New Sensitive Reversedâ€phase Highâ€performance Liquid Chromatography Method for the Quantitative Determination of Metoclopramide in Canine Plasma. Analytical Letters, 2008, 41, 767-778.	1.0	10
76	Improvement of Antiamoebic Activity of Rokitamycin Loaded in Chitosan Microspheres. Open Drug Delivery Journal, 2008, 2, 38-43.	2.0	7
77	Nasal administration of Carbamazepine using chitosan microspheres: In vitro/in vivo studies. International Journal of Pharmaceutics, 2006, 307, 9-15.	2.6	142
78	Solid Lipid Microparticles (SLM) Containing Juniper Oil as Anti-Acne Topical Carriers: Preliminary Studies. Pharmaceutical Development and Technology, 2005, 10, 479-487.	1.1	33
79	Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech, 2004, 5, 17-23.	1.5	63
80	PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 207-212.	2.0	134
81	Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug, acriflavine. AAPS PharmSciTech, 2002, 3, 32-38.	1.5	44
82	Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 53, 233-239.	2.0	161
83	Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug, acriflavine. AAPS PharmSciTech, 2002, 3, 32-38.	1.5	25